Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.20 USD
Change Today +0.04 / 1.85%
Volume 4.7M
OREX On Other Exchanges
As of 8:10 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

orexigen therapeutics inc (OREX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/15 - $9.37
52 Week Low
09/28/15 - $1.84
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

orexigen therapeutics inc (OREX) Related Businessweek News

View More BusinessWeek News

orexigen therapeutics inc (OREX) Details

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.

47 Employees
Last Reported Date: 02/27/15
Founded in 2002

orexigen therapeutics inc (OREX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $640.6K
Chief Business & Financial Officer and Treasu...
Total Annual Compensation: $379.3K
Head of Global Development and Executive Vice...
Total Annual Compensation: $379.3K
Total Annual Compensation: $379.3K
Compensation as of Fiscal Year 2014.

orexigen therapeutics inc (OREX) Key Developments

Orexigen Therapeutics, Inc. Announces Resignation of Mark Booth as Chief Commercial Officer

On September 30, 2015, Orexigen Therapeutics, Inc.entered into a Separation and Consulting Agreement with Mark Booth in connection with Mr. Booth's resignation, effective September 30, 2015 from his position as Chief Commercial Officer. Mark's Booth's departure was part of a previously announced planned transition in connection with the appointment of the Company's current EVP, Chief Commercial Officer, Tom Cannell, in March 2015.

Orexigen Therapeutics Collects $22 Million in Contrave-Linked Payments

Orexigen Therapeutics Inc. had received a combined USD 22 million (EUR 19.6 million) in payments from its US and Korean partners for weight management drug Contrave. The amount came from two payments, one of them being a USD 15 million consideration from US partner Takeda Pharmaceuticals. This was the first of three potential anniversary milestone payments of equal size. The other two are expected in the fourth quarters of 2016 and 2017. Orexigen also received USD 7 million by way of an upfront payment from Seoul-based Kwang Dong Pharmaceutical Company Ltd.

Orexigen Therapeutics Eyes Acquisitions

Orexigen Therapeutics, Inc. (NasdaqGS:OREX) is looking for acquisitions. The company plans to pursue acquisitions of a diversified portfolio of commercial assets in order to leverage the potential of commercial capabilities we may build in order to maximize profitability and shareholder value and for general working capital purposes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $2.20 USD +0.04

OREX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $2.06 USD -0.09
GlaxoSmithKline PLC 1,307 GBp -6.00
Novo Nordisk A/S kr367.00 DKK +0.70
VIVUS Inc $1.72 USD -0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation OREX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at